US Patent

US8497277 — Inhibitors of Bruton's tyrosine kinase

Method of Use · Assigned to Pharmacyclics LLC · Expires 2026-12-28 · 1y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods of using certain compounds that inhibit Bruton's tyrosine kinase for treating various diseases and conditions.

USPTO Abstract

Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-1491 — Imbruvica
U-2242 — Imbruvica
U-1946 — Imbruvica
U-2242 — Imbruvica
U-3422 — Imbruvica
U-2241 — Imbruvica
U-1946 — Imbruvica

Patent Metadata

Patent number
US8497277
Jurisdiction
US
Classification
Method of Use
Expires
2026-12-28
Drug substance claim
No
Drug product claim
No
Assignee
Pharmacyclics LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.